We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

40 hedge funds and large institutions have $32.4M invested in Bolt Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

21% more capital invested

Capital invested by funds: $26.8M → $32.4M (+$5.63M)

0.35% more ownership

Funds ownership: 2.73% → 3.08% (+0.35%)

9% less funds holding

Funds holding: 44 → 40 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
40
Holders Change
-4
Holders Change %
-9.09%
% of All Funds
0.64%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
4
Increased
13
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$1.8M
2
O
OrbiMed
New York
+$1.13M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$732K
4
Morgan Stanley
Morgan Stanley
New York
+$397K
5
JP Morgan Chase
JP Morgan Chase
New York
+$248K

Top Sellers

Rank Fund Capital Flow
1
OMC
Oasis Management Company
Cayman Islands
-$364K
2
BCM
Bridgeway Capital Management
Texas
-$164K
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$52.3K
4
NM
Newtyn Management
New York
-$51K
5
EP
Eversept Partners
New York
-$40.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$5.38M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$3.95M +$126K +4,314 +3%
SI
3
Sofinnova Investments
California
$3.83M – – –
PBPIA
4
Pivotal bioVenture Partners Investment Advisor
California
$2.63M – – –
TCM
5
Tang Capital Management
California
$2.26M +$1.8M +61,378 +307%
O
6
OrbiMed
New York
$2.14M +$1.13M +38,497 +100%
NFGH
7
Nan Fung Group Holdings
Hong Kong
$1.62M – – –
NM
8
Newtyn Management
New York
$1.55M -$51K -1,744 -3%
SB
9
Samsara BioCapital
California
$1.46M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.29M – – –
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$1M – – –
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$695K +$732K +25,000 New
Renaissance Technologies
13
Renaissance Technologies
New York
$635K +$22.2K +760 +3%
HCM
14
Hawkeye Capital Management
Florida
$577K – – –
Morgan Stanley
15
Morgan Stanley
New York
$426K +$397K +13,576 +778%
Goldman Sachs
16
Goldman Sachs
New York
$393K +$88 +3 +0%
BlackRock
17
BlackRock
New York
$381K +$1.93K +66 +0.5%
Millennium Management
18
Millennium Management
New York
$341K +$2.96K +101 +0.8%
Assenagon Asset Management
19
Assenagon Asset Management
Luxembourg
$314K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$263K +$248K +8,470 +851%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$247K +$35K +1,196 +16%
VCIM
22
Velan Capital Investment Management
Georgia
$195K +$205K +7,000 New
PFMU
23
Privium Fund Management (UK)
United Kingdom
$150K – – –
MAM
24
Marquette Asset Management
Minnesota
$136K – – –
Fidelity Investments
25
Fidelity Investments
Massachusetts
$109K – – –
1
2

BOLT Hedge Fund Activity: Q1 2023 in Review

40 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2023, worth a combined $32.4M — up 21% from $26.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BOLT and 4 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 13 added.

The largest buyer was Tang Capital Management, adding an estimated $1.8M. The largest seller was Oasis Management Company, exiting entirely with an estimated $364K sold.

  • 40 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2023, down from 44 in Q4 2022.
  • Funds reported $32.4M of Bolt Biotherapeutics stock for Q1 2023, up 21% quarter-over-quarter.
  • 4 funds opened new Bolt Biotherapeutics positions in Q1 2023 and 8 closed out, a net change of -4 holders.
  • The largest Bolt Biotherapeutics buyer in Q1 2023 was Tang Capital Management, an estimated $1.8M added.
  • The largest Bolt Biotherapeutics seller in Q1 2023 was Oasis Management Company, an estimated $364K sold.

Based on aggregated 13F filings for Q1 2023.